1. Home
  2. MESO

MESO

Mesoblast Limited

Logo Mesoblast Limited

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-24-2024 3:18pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Founded: 2004 Country:
N/A
Employees: N/A City: N/A
Market Cap: 475.9M IPO Year: N/A
Target Price: $27.33 AVG Volume (30 days): 2.2M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.91 EPS Growth: N/A
52 Week Low/High: $1.61 - $10.24 Next Earning Date: 01-01-0001
Revenue: $7,253,000 Revenue Growth: -10.69%
Revenue Growth (this year): -13.76% Revenue Growth (next year): 71.31%

Share on Social Networks: